{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCA+%28Leber+Congenital+Amaurosis%29",
    "query": {
      "condition": "LCA (Leber Congenital Amaurosis)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCA+%28Leber+Congenital+Amaurosis%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T02:42:57.321Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02575430",
      "title": "Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leber Congenital Amaurosis (LCA)",
        "Retinitis Pigmentosa (RP)"
      ],
      "interventions": [
        {
          "name": "No treatment: retrospective chart review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2015-12",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-04-29",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Portland, Oregon",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575430"
    },
    {
      "nct_id": "NCT01521793",
      "title": "Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "LCA (Leber Congenital Amaurosis)",
        "RP (Retinitis Pigmentosa)"
      ],
      "interventions": [
        {
          "name": "QLT091001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "5 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2012-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-28",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521793"
    },
    {
      "nct_id": "NCT02781480",
      "title": "Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "AAV RPE65",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MeiraGTx UK II Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-04",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781480"
    },
    {
      "nct_id": "NCT03396042",
      "title": "Natural History Study of CEP290-Related Retinal Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blindness",
        "Leber Congenital Amaurosis 10",
        "Vision Disorders",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Eye Disorders Congenital",
        "Retinal Disease",
        "Retinal Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Editas Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "3 Years to 99 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-12-17",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2022-05-19",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03396042"
    },
    {
      "nct_id": "NCT00749957",
      "title": "Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "rAAV2-CB-hRPE65",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Beacon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2009-06-17",
      "completion_date": "2017-09-22",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 2,
      "location_summary": "Worcester, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749957"
    },
    {
      "nct_id": "NCT03597399",
      "title": "A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy"
      ],
      "interventions": [
        {
          "name": "AAV2-hRPE65v2,voretigene neparvovec-rzyl",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 87,
      "start_date": "2019-01-10",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597399"
    },
    {
      "nct_id": "NCT03140969",
      "title": "Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber's Congenital Amaurosis"
      ],
      "interventions": [
        {
          "name": "QR-110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2017-10-16",
      "completion_date": "2019-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140969"
    },
    {
      "nct_id": "NCT07681778",
      "title": "Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Congenital Amaurosis",
        "Leber Congenital Amaurosis (LCA)"
      ],
      "interventions": [
        {
          "name": "OPGx-RDH12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2026-09-01",
      "completion_date": "2034-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07681778"
    },
    {
      "nct_id": "NCT05906953",
      "title": "Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leber Congenital Amaurosis",
        "Inherited Retinal Diseases Caused by RPE65 Mutations"
      ],
      "interventions": [
        {
          "name": "HG004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HuidaGene Therapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "6 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-10-31",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Houston, Texas",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05906953"
    },
    {
      "nct_id": "NCT01014052",
      "title": "Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "LCA (Leber Congenital Amaurosis)",
        "RP (Retinitis Pigmentosa)"
      ],
      "interventions": [
        {
          "name": "QLT091001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "5 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2009-11",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-05-14",
      "last_synced_at": "2026-07-22T02:42:57.321Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01014052"
    }
  ]
}